Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women

Clinical Infectious Diseases

Volumn 56, Issue 10, 2013, Pages 1488-1497

  Abzug, Mark J ^a   Nachman, Sharon A ^b   Muresan, Petronella ^c   Handelsman, Edward ^d   Watts, D Heather ^e   Fenton, Terence ^c   Heckman, Barbara ^f   Petzold, Elizabeth ^g   Weinberg, Adriana ^a   Levin, Myron J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^g SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

Author keywords

HIV infected; immunogenicity; pH1N1; pregnancy; vaccine

Indexed keywords

CD4 ANTIGEN; HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; MATERNAL ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILL; DRUG SAFETY; FEMALE; FETUS DEATH; GESTATIONAL AGE; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE DYSREGULATION; IMMUNOGENICITY; INFLUENZA VACCINATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; REGULATORY T LYMPHOCYTE; RHINORRHEA; SIDE EFFECT; THIRD TRIMESTER PREGNANCY; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; CHI-SQUARE DISTRIBUTION; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84877288220     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit057     Document Type: Article

References (39)

1. Bergman H, Livornese LL Jr., Sambhara S, Santaro J, Dessain SK. Patients hospitalized with pH1N1 influenza in an academic community medical center. Open Respir Med J 2011; 5:19-23.
2. Dolan GP, Myles PR, Brett SJ, et al. The comparative clinical course of pregnant and non-pregnant women hospitalized with influenza A (H1N1)pdm09 infection. PLoS One 2012; 7:e41638.
3. Dubar G, Azria E, Tesnière A, et al. French experience of 2009 A/H1N1v influenza in pregnant women. PLoS One 2010; 5: p.e13112.
4. Goldstein E, Lipsitch M. H1N1 vaccination and adults with underlying health conditions in the US. PLoS Curr 2009; 1:RRN1132.
5. Jackson LA, Patel S, Swamy GK, et al. Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. J Infect Dis 2011; 204:854-63.
6. Kay MK, Koelemay KG, Kwan-Gett TS, Cadwell BL, Duchin JS. 2009 pandemic influenza A vaccination of pregnant women: King County, Washington State, 2009-2010. Am J Prev Med 2012; 42:S172-S179.
7. Fisher BM, Van Bockern J, Hart J, et al. Pandemic influenza A H1N1 2009 infection versus vaccination: a cohort study comparing immune responses in pregnancy. PLoS One 2012; 7:e33048.
8. Zuccotti G, Pogliani L, Pariani E, Amendola A, Zanetti A. Transplacental antibody transfer following maternal immunization with a pandemic 2009 influenza A(H1N1) MF-59-adjuvanted vaccine. JAMA 2010; 304:2360-1.
9. Gilca R, De Serres G, Boulianne N, et al. Risk factors for hospitalization and severe outcomes of 2009 pandemic H1N1 influenza in Quebec, Canada. Influenza Other Respi Viruses 2011; 5:247-55.
10. Cooper CL. Pandemic H1N12009 influenza and HIV: a review of natural history, management, and vaccine immunogenicity. Curr Opin Infect Dis 2012; 25:26-35.
11. Peters PJ, Skarbinski J, Louie JK, et al. HIV-infected hospitalized patients with 2009 pandemic influenza A (pH1N1)-United States, spring and summer 2009. Clin Infect Dis 2011; 52(suppl 1):S183-8.
12. Sheth AN, Patel P, Peters PJ. Influenza and HIV: lessons from the 2009 H1N1 influenza pandemic. Curr HIV/AIDS Rep 2011; 8:181-91.
13. Flynn PM, Nachman S, Muresan P, et al. Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. J Infect Dis 2012; 206:421-30.
14. Heikkinen T, Young J, van Beek E, et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am J Obstet Gynecol 2012; 207:177.e1-8.
15. Kallen B, Olausson PO. Vaccination against H1N1 influenza with Pandemrix during pregnancy and delivery outcome: a Swedish register study. BJOG 2012; 119:1583-90.
16. Oppermann M, Fritzsche J, Weber-Schoendorfer C, et al. A(H1N1) v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy. Vaccine 2012; 30:4445-52.
17. Pasternak B, Svanstrom H, Molgaard-Nielsen D, et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A (H1N1) vaccine during pregnancy. JAMA 2012; 308:165-74.
18. Pasternak B, Svanstrom H, Molgaard-Nielsen D, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ 2012; 344:e2794.
19. Tsatsaris V, Capitant C, Schmitz T, et al. Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 influenza A(H1N1) vaccine: a single-group trial. Ann Intern Med 2011; 155:733-41.
20. Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIVinfected adults with HIV-uninfected adults. Clin Infect Dis 2011; 52: 138-46.
21. Phongsamart W, Sirisanthana V, Wittawatmongkol O, et al. Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIVinfected Thai children. Vaccine 2011; 29:8705-11.
22. Horiya M, Hisano M, Iwasaki Y, et al. Efficacy of double vaccination with the 2009 pandemic influenza A (H1N1) vaccine during pregnancy. Obstet Gynecol 2011; 118:887-94.
23. Ohfuji S, Fukushim W, Deguchi M, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine among pregnant women: lowered antibody response by prior seasonal vaccination. J Infect Dis 2011; 203:1301-8.
24. Novartis H1N1 vaccine in pregnant women. Study NCT00992719. Available at: http://clinicaltrials.gov/ct2/show/results/NCT00992719. Accessed 15 October 2012.
25. Lagler H, Grabmeier-Pfistershammer K, Touzeau-Romer V, et al. Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals. PLoS One 2012; 7:e36773.
26. Launay O, Desaint C, Durier C, et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis 2011; 204:124-34.
27. Maruszak H, Jeganathan S, Smith DE, Robertson P, Barnes T, Furner V. Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the southern hemisphere. HIV Med 2012; 13:352-7.
28. Tebas P, Frank I, Lewis M, et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010; 24:2187-92.
29. Tiu CT, Lin YS, Pagala M, et al. Antibody responses to inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with and without HIV. J Acquir Immune Defic Syndr 2011; 58:e99-102.
30. El Sahly HM, Davis C, Kotloff K, et al. Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIVinfected adults: a randomized clinical trial. J Infect Dis 2012; 205:703-12.
31. Hakim H, Allison KJ, Van De Velde L, Li Y, Flynn PM, McCullers JA. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults. Vaccine 2012; 30:879-85.
32. Richardson K, Weinberg A. Reduced immunogenicity of influenza vaccines in HIV-infected compared to uninfected pregnant women is associated with regulatory T cells. AIDS 2011; 25:595-602.
33. Bickel M, von Hentig N, Wieters I, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis 2011; 52: 122-7.
34. Cooper C, Klein M, Walmsley S, et al. High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with boosting dosing in a randomized trial of HIV-infected adults. HIV Clin Trials 2012; 13:23-32.
35. Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 monovalent ASO3-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011; 52:248-56.
36. Soonawala D, Rimmelzwaan GJ, Gelinck LBS, Visser LG, Kroon FP. Response to 2009 pandemic influenza A (H1N1) vaccine in HIVinfected patients and the influence of prior seasonal influenza vaccination. PLoS One 2011; 6:e16496.
37. Puleston RL, Bugg G, Hoschler K, et al. Observational study to investigate vertically acquired passive immunity in babies of mothers vaccinated against H1N1v during pregnancy. Health Technol Assess 2010; 14:1-82.
38. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008; 359:1555-64.
39. Steinhoff MC, Omer SB, Roy E, et al. Influenza immunization in pregnancy-antibody responses in mothers and infants. N Engl J Med 2010; 362:1644-6.